Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers

被引:33
|
作者
Nobashi, Tomomi W. [1 ]
Nishimoto, Yuko [1 ]
Kawata, Yujiro [1 ]
Yutani, Hidetaka [1 ]
Nakamura, Masaki [1 ]
Tsuji, Yuichi [1 ]
Yoshida, Atsushi [1 ]
Sugimoto, Akihiko [1 ]
Yamamoto, Takayuki [1 ]
Alam, Israt S. [2 ]
Noma, Satoshi [1 ]
机构
[1] Tenri Hosp, Dept Radiol, Nara, Japan
[2] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA USA
来源
BRITISH JOURNAL OF RADIOLOGY | 2020年 / 93卷 / 1115期
关键词
ADVERSE EVENTS; POOLED ANALYSIS; DEATH; NIVOLUMAB; THERAPY; KL-6; IPILIMUMAB; BLOCKADE; SMOKING; RISK;
D O I
10.1259/bjr.20200409
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients. Methods: 247 patients (LC, n = 151) treated with ICI for malignancies were retrospectively screened in a single institute. The number of patients, history of other immune-related adverse events (irAE), the onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, laterality, location) were recorded for the ICI-P population and compared for LC and non-LC groups. Results: ICI-P was identified in 26 patients in total (LC, n = 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, irrespective of primary disease, were organizing pneumonia pattern and ground glass opacities. LC patients commonly exhibited consolidation and traction bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC patients were more likely to exhibit symmetrical infiltrations. A small fraction of both groups experienced relapse or moving patterns of ICI-P. Conclusion: ICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients. Advances in knowledge: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Immune Checkpoint Inhibitor Associated Pneumonitis In Lung Cancer
    Juenger, K.
    Abdulhaq, H.
    Bilello, K.
    Upadhyay, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [32] Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
    Chitturi, Kalyan R.
    Xu, Jiaqiong
    Araujo-Gutierrez, Raquel
    Bhimaraj, Arvind
    Guha, Ashrith
    Hussain, Imad
    Kassi, Mahwash
    Bernicker, Eric H.
    Trachtenberg, Barry H.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 182 - 192
  • [33] Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients
    Sun, Xiaojun
    Song, Zhengbo
    Jiang, Hongyang
    Ma, Yanqing
    Chen, Ming
    CLINICAL IMAGING, 2022, 86 : 31 - 37
  • [34] Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study
    Lin, X.
    Lu, T.
    Li, S.
    Xie, X.
    Chen, X.
    Jiang, J.
    Qin, Y.
    Xie, Z.
    Liu, M.
    Ouyang, M.
    Zhong, N.
    Song, Y.
    Zhou, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (02): : 389 - 396
  • [35] Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer
    Hu, Qiongjie
    Wang, Shaofang
    Ma, Li
    Sun, Ziyan
    Liu, Zilin
    Deng, Shuang
    Zhou, Jianlin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (05)
  • [36] Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study
    X. Lin
    T. Lu
    S. Li
    X. Xie
    X. Chen
    J. Jiang
    Y. Qin
    Z. Xie
    M. Liu
    M. Ouyang
    N. Zhong
    Y. Song
    C. Zhou
    Clinical and Translational Oncology, 2021, 23 : 389 - 396
  • [37] Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
    Chuzi, Sarah
    Tavora, Fabio
    Cruz, Marcelo
    Costa, Ricardo
    Chae, Young Kwang
    Carneiro, Benedito A.
    Giles, Francis J.
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 207 - 213
  • [38] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC)
    Yadav, Monica
    Lee, Jeeyeon
    Kim, Haseok
    Lee, Seyoung
    Um, Taegyu
    Lee, Salie
    Djunadi, Trie Arni
    Chung, Liam Il Young
    Yu, Jisang
    Rodrigues, Darren
    Gennaro, Nicolo
    Kim, Leeseul
    Kim, Yuchan
    Nam, Myungwoo
    Hong, Ilene
    Jang, Jessica
    Cho, Amy
    Kang, Grace
    Velichko, Yury
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
    Wang, Shiyang
    Tian, Binhe
    Wang, Hanping
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17
  • [40] Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer Is Routine Screening Indicated?
    Sun, Lova
    Aggarwal, Charu
    Cohen, Roger B.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 193 - 195